TCGA-OR-A5LS-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- FATTY_ACID_METABOLISM+0.249
- INTERFERON_ALPHA_RESPONSE+0.247
- PROTEIN_SECRETION+0.230
- BILE_ACID_METABOLISM+0.162
- SPERMATOGENESIS+0.158
- KRAS_SIGNALING_DN+0.142
- OXIDATIVE_PHOSPHORYLATION+0.136
- HEME_METABOLISM+0.132
- MYC_TARGETS_V2+0.094
- PEROXISOME+0.062
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.444
- ANGIOGENESIS-0.438
- TNFA_SIGNALING_VIA_NFKB-0.408
- HYPOXIA-0.384
- ALLOGRAFT_REJECTION-0.360
- IL6_JAK_STAT3_SIGNALING-0.349
- IL2_STAT5_SIGNALING-0.343
- INFLAMMATORY_RESPONSE-0.324
- WNT_BETA_CATENIN_SIGNALING-0.320
- APOPTOSIS-0.313
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-QK-A8Z8-01A-11R-A39I-07 | — | — | 0.874 |
| 2 | SRR659484 | GTEX | — | 0.851 |
| 3 | SRR11296802 | — | — | 0.820 |
| 4 | SRR664854 | GTEX | — | 0.798 |
| 5 | MNG37 | — | — | 0.797 |
| 6 | SRR8518272 | — | E | 0.794 |
| 7 | AUR-AD9H-TTM2-A-1-1-R-A542-39 | — | B | 0.793 |
| 8 | TCGA-OR-A5LB-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.786 |
| 9 | SRR655649 | GTEX | — | 0.783 |
| 10 | AUR-AFE9-TTM1-A-1-1-R-A742-41 | — | B | 0.781 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| FATTY_ACID_METABOLISM | 0.249 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.247 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.162 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.158 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.142 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.136 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.132 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.094 | Idelalisib | — uncovered |
| PEROXISOME | 0.062 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.001 | Inavolisib | — uncovered |